Clinical trial
AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS® IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
NCT03371108 is registered in ClinicalTrials.gov with Gan and Lee Pharmaceuticals, USA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- AN OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE 3 STUDY TO COMPARE THE IMMUNOGENICITY, EFFICACY, AND SAFETY OF GAN & LEE PHARMACEUTICALS INSULIN GLARGINE INJECTION TO LANTUS® IN ADULT SUBJECTS WITH TYPE 2 DIABETES MELLITUS
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 31, 2017
- Completion date
- April 17, 2019
- Enrollment
- 567 (actual)
- Sites
- 57
Conditions
As the registry lists them; a condition with its own page is linked.